![](https://www.diabetesnews.com/wp-content/uploads/2014/02/1376258597_Metformin-150x150.jpg)
The revelation, published in the journal Diabetes Care, means that a delayed-release form of metformin that the researchers tested could suit the 40% of type 2 diabetes patients who cannot use the current formulation.
The revelation, published in the journal Diabetes Care, means that a delayed-release form of metformin that the researchers tested could suit the 40% of type 2 diabetes patients who cannot use the current formulation.